Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to determine the best safe dose of xevinapant that can be
given in combination with chemotherapy and radiation in patients with head and neck cancer.
Up to 4 doses of xevinapant will be tested in the dose escalation portion of the study. After
the best safe dose is found during escalation, an additional group of participants will be
enrolled at that dose to learn more about the treatment combination (dose expansion).
The main question[s] it aims to answer are:
- what is the maximum safe dose that can be given
- what dose should be used in subsequent (phase 2) trials
Participants will receive xevinapant in combination with paclitaxel and carboplatin
chemotherapy and radiation. Treatment will be given in 3-week cycles for 3 cycles.